1
3-1 Report: Potential Alternative Buyers/Competitor Research
Shavonte Peterson
Southern New Hampshire University
MBA – 699: Strategic Opportunity Management
Professor Jessica Perez
September 14, 2025
2
Introduction
The owners of our organization are eager to sell. After forming a team to guide the
process and examining employee statistics to address any concerns potential buyers might have
about staff turnover, the focus now shifts to what happens next after the sale. However, an
unexpected challenge has come up regarding the next steps in the selling strategy. Due to the
current market conditions and economic uncertainty, the potential buyer is reconsidering their
decision to purchase the organization. It's essential to explore other potential buyers, as well as
develop a backup plan to prepare for any issues that may arise if this buyer decides not to
proceed with the purchase. To demonstrate to the Vice President that options are available if we
need another buyer, we will explore three businesses in the same industry during this phase of
the process.
North American Industry Classification System (NAICS) Code
For our life sciences corporation, which produces pharmaceutical preparations and
medications for cancer treatment, the most pertinent NAICS Code is 325412. This category
includes businesses that create medicines and herbal products. To identify potential buyers
within this sector, access industry databases and directories such as IBISWorld, Mergent Online,
or MarketLine. By searching under this code and related classifications (such as 32541 for
Pharmaceutical and Medicine Manufacturing), we can pinpoint companies within the oncology
and broader pharmaceutical landscape that align with our company's capabilities and may be
interested in strategic acquisitions or partnerships.
Top Competitors
The leading candidates for acquisition within the Pharmaceutical Preparation
Manufacturing sector include the esteemed giants Pfizer Inc., Johnson & Johnson (J&J), and
3
Bristol-Myers Squibb. These companies have been identified after a comprehensive assessment
based on several critical criteria, which encompass their significant advancements in oncology
product development, unwavering commitment to pioneering innovative cancer treatments, and a
distinguished history of maintaining robust and profitable operations. Pfizer Inc., founded in
1849, boasts an impressive 176 years of industry expertise. Over the decades, it has cultivated a
formidable reputation for research and development, particularly in the area of oncology, making
it a noteworthy player in the pharmaceutical landscape.
Johnson & Johnson, established in 1886, brings 139 years of experience, characterized by
its diverse portfolio, which spans consumer health products, medical devices, and
pharmaceuticals, all highlighted by its dedication to improving health and well-being globally.
Bristol-Myers Squibb, with its roots tracing back to 1887, is set to commemorate its 138th
anniversary in 2025. The company has established itself as a leader in the pharmaceutical sector,
particularly renowned for its groundbreaking treatments in cancer care and immunotherapy. Each
of these companies not only has a solid portfolio of products but also a legacy of innovation in
the oncology field, positioning them as formidable contenders in any prospective acquisition
scenario. Their collective expertise and commitment to advancing cancer treatment make them
vital players in the evolving pharmaceutical landscape.
Company Information
Pfizer's current mission isAto be the premier innovative biopharmaceutical company,
making breakthroughs that change patients' lives.AThis is supported by their purpose and core
values, which emphasize applying science and global resources to improve health and well-being
for all.APfizer has developed some of the world's most impactful medicines and vaccines,
including a best-selling over-the-counter pain reliever, a popular medicine for anxiety and panic
4
disorder management, an erectile dysfunction treatment, a vaccine to help provide protection
against COVID-19, and an oral COVID-19 prescription treatment for patients at high risk of
progressing to severe COVID-19. The company generated $63.63 billion in revenue for the 12
months ending in Q2 2025, representing approximately 7.1% of the total market revenue at that
time.APfizer's revenue CAGR is approximately 9.2% from 2019 to 2024. Over the past 13 years,
the operating income CAGR has declined by -1%, but projections for the next three years
suggest a recovery, with an expected 10% CAGR in operating income.
Johnson & Johnson's strategic vision focuses onApreventing, treating, and curing complex
diseases by innovating in its core areas of Innovative Medicine and MedTech, aiming for smarter
and less invasive solutions.AKey to this vision is creating a world with global health equity,
improving access to care, and fostering a healthy mind, body, and environment for all.AThe
company prioritizes R&D, strategic partnerships, and sustainability to achieve these ambitious
goals.AJohnson & Johnson's overall market share was 5.52% as of the second quarter of 2025.
This figure is based on the company's revenues relative to its competitors in the healthcare sector
during that period, with a total 12-month revenue of $90.627 billion.AThe company's revenue has
experienced a compound annual growth rate (CAGR) of 2% over the past 13 years, with
forecasts suggesting an increase to 5% CAGR for the upcoming 3-year period.
Bristol Myers Squibb's strategic vision isAto be the world's leading biopharmaceutical
company, transforming patients' lives through science by focusing on discovering, developing,
and delivering innovative medicines for serious diseases.AThis vision is supported by a strategy
that emphasizes innovation in breakthrough science, strategic partnerships, and addressing high
unmet medical needs, alongside a commitment to expanding patient access to therapies and
promoting health equity and sustainability.AThe company generated $47.704 billion in revenue
5
for the 12 months ending in Q2 2025, representing approximately 5.84% of the total market
revenue at that time and 11.5%Aof the Brand Name Pharmaceutical Manufacturing market in the
US. Bristol-Myers Squibb has achieved a compound annual growth rate (CAGR) of 12.8% in
revenue over the past seven years.
Conclusion
Considering that the three selected companies specialize in treatment, vaccines, and
medications, we have conducted a comprehensive evaluation of each organization before
proceeding with an offer. This review contains an analysis of their financial health, product
pipelines, and market positioning. Additionally, understanding their research and development
capabilities, intellectual property assets, and competitive advantages will provide invaluable
insights. By thoroughly investigating these aspects, we can make a well-informed decision that
aligns with our strategic objectives and risk tolerance in the healthcare sector.
6
References
Johnson & Johnson. (2025).AOur Company. Content Lab U.S. https://www.jnj.com/our-company
Mission, Vision & Values of Bristol-Myers Squibb Company. (2025). Www.bms.com.
https://www.bms.com/about-us/our-company/our-mission.html
Pfizer. (2025).APfizer’s Purpose, Core Values, and Purpose Blueprint | Pfizer. Www.pfizer.com.
https://www.pfizer.com/about/purpose
Search for Shares, Industries, News and Economic Indicators - CSI Market. (2025).
Csimarket.com. https://csimarket.com/stocks/competitionSEG2.php?
The Complete Toolbox for Investors | finbox.com. (2025). Finbox.com.
https://finbox.com/NYSE:BMY/explorer/total_rev_cagr_7y/
What is a NAICS Code and Why Do I Need One?A(2024, November 15). NAICS Association.
https://www.naics.com/what-is-a-naics-code/
